Literature DB >> 32026417

Interleukin-36: Structure, Signaling and Function.

Li Zhou1, Viktor Todorovic2.   

Abstract

The IL-36 family belongs to a larger IL-1 superfamily and consists of three agonists (IL-36α/β/γ), one antagonist (IL-36Ra), one cognate receptor (IL-36R) and one accessory protein (IL-1RAcP). The receptor activation follows a two-step mechanism in that the agonist first binds to IL-36R and the resulting binary complex recruits IL-1RAcP. Assembled ternary complex brings together intracellular TIR domains of receptors which activate downstream NF-κB and MAPK signaling. Antagonist IL-36Ra inhibits the signaling by binding to IL-36R and preventing recruitment of IL-1RAcP. Members of IL-36 are normally expressed at low levels. Upon stimulation, they are inducted and act on a variety of cells including epithelial and immune cells. Protease mediated N-terminal processing is needed for cytokine activation. In the skin, the functional role of IL-36 is to contribute to host defense through inflammatory response. However, when dysregulated, IL-36 stimulates keratinocyte and immune cells to enhance the Th17/Th23 axis and induces psoriatic-like skin disorder. Genetic mutations of the antagonist IL-36Ra are associated with occurrence of generalized pustular psoriasis, a rare but life-threatening skin disease. Anti-IL-36 antibodies attenuate IMQ or IL-23 induced skin inflammation in mice, illustrating IL-36's involvement in mouse model of psoriasis. Other organs such as the lungs, the intestine, the joints and the brain also express IL-36 family members upon stimulation. The physiological and pathological roles of IL-36 are less well defined in these organs than in the skin. In this chapter, current progress on IL-36 protein and biology is reviewed with a discussion on investigative tools for this novel target.

Entities:  

Keywords:  Generalized pustular psoriasis; IL-1 superfamily; IL-36; Inflammation; Psoriasis; Therapeutics

Mesh:

Substances:

Year:  2021        PMID: 32026417     DOI: 10.1007/5584_2020_488

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  122 in total

1.  Binding of small molecules to an adaptive protein-protein interface.

Authors:  Michelle R Arkin; Mike Randal; Warren L DeLano; Jennifer Hyde; Tinh N Luong; Johan D Oslob; Darren R Raphael; Lisa Taylor; Jun Wang; Robert S McDowell; James A Wells; Andrew C Braisted
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-11       Impact factor: 11.205

2.  An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.

Authors:  Ivona Aksentijevich; Seth L Masters; Polly J Ferguson; Paul Dancey; Joost Frenkel; Annet van Royen-Kerkhoff; Ron Laxer; Ulf Tedgård; Edward W Cowen; Tuyet-Hang Pham; Matthew Booty; Jacob D Estes; Netanya G Sandler; Nicole Plass; Deborah L Stone; Maria L Turner; Suvimol Hill; John A Butman; Rayfel Schneider; Paul Babyn; Hatem I El-Shanti; Elena Pope; Karyl Barron; Xinyu Bing; Arian Laurence; Chyi-Chia R Lee; Dawn Chapelle; Gillian I Clarke; Kamal Ohson; Marc Nicholson; Massimo Gadina; Barbara Yang; Benjamin D Korman; Peter K Gregersen; P Martin van Hagen; A Elisabeth Hak; Marjan Huizing; Proton Rahman; Daniel C Douek; Elaine F Remmers; Daniel L Kastner; Raphaela Goldbach-Mansky
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

3.  Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α.

Authors:  Inna S Afonina; Graham A Tynan; Susan E Logue; Sean P Cullen; Michael Bots; Alexander U Lüthi; Emer P Reeves; Noel G McElvaney; Jan P Medema; Ed C Lavelle; Seamus J Martin
Journal:  Mol Cell       Date:  2011-10-21       Impact factor: 17.970

Review 4.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

Authors:  Michelle R Arkin; Yinyan Tang; James A Wells
Journal:  Chem Biol       Date:  2014-09-18

5.  IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.

Authors:  Helena Ågerstam; Nils Hansen; Sofia von Palffy; Carl Sandén; Kristian Reckzeh; Christine Karlsson; Henrik Lilljebjörn; Niklas Landberg; Maria Askmyr; Carl Högberg; Marianne Rissler; Kimmo Porkka; Hans Wadenvik; Satu Mustjoki; Johan Richter; Marcus Järås; Thoas Fioretos
Journal:  Blood       Date:  2016-09-12       Impact factor: 22.113

6.  Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Authors:  Helena Ågerstam; Christine Karlsson; Nils Hansen; Carl Sandén; Maria Askmyr; Sofia von Palffy; Carl Högberg; Marianne Rissler; Mark Wunderlich; Gunnar Juliusson; Johan Richter; Kjell Sjöström; Ravi Bhatia; James C Mulloy; Marcus Järås; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

7.  Serum level of interleukin 36 in patients with multiple sclerosis.

Authors:  Fereshteh Alsahebfosoul; Hamidreza Jahanbani-Ardakani; Reza Ghavimi; Nahid Sedaghat; Masoud Etemadifar
Journal:  J Immunoassay Immunochem       Date:  2018-09-25

8.  Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ.

Authors:  Joseph S Ainscough; Tom Macleod; Dennis McGonagle; Rosella Brakefield; Jens M Baron; Ade Alase; Miriam Wittmann; Martin Stacey
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-13       Impact factor: 11.205

9.  Interleukin-36γ and IL-36 receptor signaling mediate impaired host immunity and lung injury in cytotoxic Pseudomonas aeruginosa pulmonary infection: Role of prostaglandin E2.

Authors:  Tetsuji Aoyagi; Michael W Newstead; Xianying Zeng; Yuta Nanjo; Marc Peters-Golden; Mitsuo Kaku; Theodore J Standiford
Journal:  PLoS Pathog       Date:  2017-11-22       Impact factor: 6.823

10.  IL-36 receptor deletion attenuates lung injury and decreases mortality in murine influenza pneumonia.

Authors:  T Aoyagi; M W Newstead; X Zeng; S L Kunkel; M Kaku; T J Standiford
Journal:  Mucosal Immunol       Date:  2016-12-14       Impact factor: 7.313

View more
  8 in total

Review 1.  IL-36 in chronic inflammation and fibrosis - bridging the gap?

Authors:  Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 2.  IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications.

Authors:  Helena Iznardo; Luís Puig
Journal:  Int J Mol Sci       Date:  2022-08-22       Impact factor: 6.208

3.  IL-36 receptor agonist and antagonist imbalance drives neutrophilic inflammation in COPD.

Authors:  Jonathan R Baker; Peter S Fenwick; Carolin K Koss; Harriet B Owles; Sarah L Elkin; Jay Fine; Matthew Thomas; Karim C El Kasmi; Peter J Barnes; Louise E Donnelly
Journal:  JCI Insight       Date:  2022-08-08

4.  Altered serum levels of IL-36 cytokines (IL-36α, IL-36β, IL-36γ, and IL-36Ra) and their potential roles in Guillain-Barré syndrome.

Authors:  Zhikang Zhao; Rui Zhang; Xinxin Gao; Hui Li; Hongbo Liu
Journal:  Medicine (Baltimore)       Date:  2020-12-24       Impact factor: 1.817

Review 5.  Biological Role, Mechanism of Action and the Importance of Interleukins in Kidney Diseases.

Authors:  Paulina Mertowska; Sebastian Mertowski; Iwona Smarz-Widelska; Ewelina Grywalska
Journal:  Int J Mol Sci       Date:  2022-01-07       Impact factor: 5.923

6.  IL-36γ and IL-36Ra Reciprocally Regulate Colon Inflammation and Tumorigenesis by Modulating the Cell-Matrix Adhesion Network and Wnt Signaling.

Authors:  Wei Yang; Hong-Peng Dong; Peng Wang; Zhi-Gao Xu; Jiahuan Xian; Jiachen Chen; Hai Wu; Yang Lou; Dandan Lin; Bo Zhong
Journal:  Adv Sci (Weinh)       Date:  2022-02-04       Impact factor: 16.806

7.  Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Zhi-Jie Liu; Yu-Tong Tian; Bo-Yi Shi; Yin Zhou; Xue-Song Jia
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

8.  IL-36γ and IL-36Ra Reciprocally Regulate NSCLC Progression by Modulating GSH Homeostasis and Oxidative Stress-Induced Cell Death.

Authors:  Peng Wang; Wei Yang; Hao Guo; Hong-Peng Dong; Yu-Yao Guo; Hu Gan; Zou Wang; Yongbo Cheng; Yu Deng; Shizhe Xie; Xinglou Yang; Dandan Lin; Bo Zhong
Journal:  Adv Sci (Weinh)       Date:  2021-08-08       Impact factor: 16.806

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.